Abzena : Block Listing Update

Abzena plc

Block Listing Update

Cambridge, UK, 3 January 2018- Further to the announcement by Abzena plc (AIM: ABZA, 'Abzena' or the 'Group')on 3 July 2017, between 4 July 2017 and 3 January 2018, the Group announces that a total of 213,227 ordinary shares of £0.002 each in the share capital of the Group ('Ordinary Shares') have been issued pursuant to the Group's 2013 Share Incentive Plan and admitted to trading in accordance with the block listing applied for on 7 July 2015 (the 'Block Listing'). An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below. Abzena holds no shares in treasury and hence the total number of current voting rights is 213,817,130.

BLOCK LISTING SIX MONTHLY RETURN

Name of applicant:		Abzena plc
Name of scheme:		Abzena plc 2013 Share Incentive Plan
Period of return:	From:	4 July 2017	To:	3 January 2018
Balance of unallotted securities under scheme(s) from previous return:		757,476
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil
Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):		213,227
Equals: Balance under scheme(s) not yet issued/allotted at end of period		544,249
Number and class of securities originally admitted and the date of admission		1,779,000 ordinary shares of £0.002 each, admitted on 13 July 2015
Name of contact:		Julian Smith
Telephone number of contact:		[phone]

-Ends-

Enquiries:

Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer	[phone]
Numis(Nominated Adviser and Broker) Clare Terlouw / James Black / Paul Gillam	[phone]
N+1 Singer(Joint Broker) Aubrey Powell / Liz Yong	[phone]
Instinctif Partners Melanie-Toyne Sewell / Alex Shaw	[phone] [e-mail]

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENA Inside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on 'ABZENA Inside' products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

· Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products;

· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

· Cell line development for the manufacture of recombinant proteins and antibodies;

· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

· Proprietary site-specific conjugation technologies and novel payloads for ADC development; and

· GMP manufacturer of ADC linkers, payloads & combined linker-payloads.

For more information, please seewww.abzena.com.